Literature DB >> 32978281

Discordance between Serum Neutralizing Antibody Titers and the Recovery from COVID-19.

Merve Kalkan Yazıcı1, Meliha Meric Koç2, Nesibe Selma Çetin1,3, Elif Karaaslan1, Gulay Okay2, Bulent Durdu2, Bilge Sümbül3, Mehmet Z Doymaz4,3.   

Abstract

The recent pandemic of COVID-19 has caused a tremendous alarm around the world. Details of the infection process in the host have significant bearings on both recovery from the disease and on the correlates of the protection from the future exposures. One of these factors is the presence and titers of neutralizing Abs (NAbs) in infected people. In the current study, we set out to investigate NAbs in the recovered subjects discharged from the hospital in full health. Serum samples from a total of 49 documented consecutive COVID-19 subjects were included in the study. All the subjects were adults, and serum samples collected during the discharge were tested in viral neutralization, enzyme immunoassay (EIA), and Western immunoblot tests against viral Ags. Even though a majority of the recovered subjects had raised significant NAb titers, there is a substantial number of recovered patients (10 out of 49) with no or low titers of NAbs against the virus. In these cohorts as well as in patients with high NAb titers, viral Ag binding Abs were detectable in EIA tests. Both NAb titers and EIA detectable Abs are increased in patients experiencing a severe form of the disease, and in older patients the Ab titers were heightened. The main conclusion is that the recovery from SARS-CoV-2 infection is not solely dependent on high NAb titers in affected subjects, and this recovery process is probably produced by a complex interplay between many factors, including immune response, age of the subjects, and viral pathology.
Copyright © 2020 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32978281     DOI: 10.4049/jimmunol.2000840

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

Review 1.  Practical guidance for clinical laboratories for SARS-CoV-2 serology testing.

Authors:  Carmen Charlton; Jamil Kanji; Vanessa Tran; Julianne Kus; Jonathan Gubbay; Carla Osiowy; Jason Robinson; Inna Sekirov; Michael Drebot; Todd Hatchette; Derek Stein; Nadia El-Gabalawy; Amanda Lang; Lei Jiao; Paul Levett; Heidi Wood; Christian Therrien; L Robbin Lindsay; Muhammad Morshed; Jessica Forbes; Antonia Dibernardo
Journal:  Can Commun Dis Rep       Date:  2021-05-07

2.  Characterization of neutralizing versus binding antibodies and memory B cells in COVID-19 recovered individuals from India.

Authors:  Kaustuv Nayak; Kamalvishnu Gottimukkala; Sanjeev Kumar; Elluri Seetharami Reddy; Venkata Viswanadh Edara; Robert Kauffman; Katharine Floyd; Grace Mantus; Deepali Savargaonkar; Pawan Kumar Goel; Satyam Arora; Manju Rahi; Carl W Davis; Susanne Linderman; Jens Wrammert; Mehul S Suthar; Rafi Ahmed; Amit Sharma; Kaja Murali-Krishna; Anmol Chandele
Journal:  Virology       Date:  2021-03-05       Impact factor: 3.513

3.  Impact of both socioeconomic level and occupation on antibody prevalence to SARS-CoV-2 in an Egyptian cohort: The first episode.

Authors:  Mahmoud M Bahgat; Rola Nadeem; Mohamed H Nasraa; Mona A-E Awad; Solaf Kamel; Dina N Abd-Elshafy
Journal:  J Med Virol       Date:  2021-02-19       Impact factor: 20.693

4.  Impact of Convalescent Plasma Therapy on Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Antibody Profile in Coronavirus Disease 2019 (COVID-19) Patients.

Authors:  Juanjie Tang; Gabrielle Grubbs; Youri Lee; Hana Golding; Surender Khurana
Journal:  Clin Infect Dis       Date:  2022-01-29       Impact factor: 9.079

5.  SARS-CoV-2 Serum Neutralization Assay: A Traditional Tool for a Brand-New Virus.

Authors:  Giulia Matusali; Francesca Colavita; Daniele Lapa; Silvia Meschi; Licia Bordi; Pierluca Piselli; Roberta Gagliardini; Angela Corpolongo; Emanuele Nicastri; Andrea Antinori; Giuseppe Ippolito; Maria Rosaria Capobianchi; Concetta Castilletti
Journal:  Viruses       Date:  2021-04-10       Impact factor: 5.048

6.  Nucleic acid delivery of immune-focused SARS-CoV-2 nanoparticles drives rapid and potent immunogenicity capable of single-dose protection.

Authors:  Kylie M Konrath; Kevin Liaw; Yuanhan Wu; Xizhou Zhu; Susanne N Walker; Ziyang Xu; Katherine Schultheis; Neethu Chokkalingam; Himanshi Chawla; Jianqiu Du; Nicholas J Tursi; Alan Moore; Jared Adolf-Bryfogle; Mansi Purwar; Emma L Reuschel; Drew Frase; Matthew Sullivan; Benjamin Fry; Igor Maricic; Viviane M Andrade; Christel Iffland; Max Crispin; Kate E Broderick; Laurent M P F Humeau; Ami Patel; Trevor R F Smith; Jesper Pallesen; David B Weiner; Daniel W Kulp
Journal:  Cell Rep       Date:  2022-01-11       Impact factor: 9.995

Review 7.  Biology of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and the humoral immunoresponse: a systematic review of evidence to support global policy-level actions and research.

Authors:  Shalini Nair; Xinguang Chen
Journal:  Glob Health J       Date:  2021-11-19

8.  SARS-CoV-2 neutralizing capacity among blood donors without prior COVID-19 symptomatic history vs. blood donors with prior COVID-19 symptomatic history: A comparative study.

Authors:  Ushasree Ravula; Srinivasa Rao Chunchu; Srujaleswari Mooli; Ravi Naik; Pandu Ranga Rao Sarangapati
Journal:  Transfus Clin Biol       Date:  2022-02-12       Impact factor: 2.126

9.  Utility of Different Surrogate Enzyme-Linked Immunosorbent Assays (sELISAs) for Detection of SARS-CoV-2 Neutralizing Antibodies.

Authors:  Niko Kohmer; Cornelia Rühl; Sandra Ciesek; Holger F Rabenau
Journal:  J Clin Med       Date:  2021-05-14       Impact factor: 4.241

10.  Extracellular vesicles carry SARS-CoV-2 spike protein and serve as decoys for neutralizing antibodies.

Authors:  Zach Troyer; Najwa Alhusaini; Caroline O Tabler; Thomas Sweet; Karina Inacio Ladislau de Carvalho; Daniela M Schlatzer; Lenore Carias; Christopher L King; Kenneth Matreyek; John C Tilton
Journal:  J Extracell Vesicles       Date:  2021-06-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.